Platelet Activity in the Early Stage of Acute Myocardial Infarction: Relation to Time of Presentation, Treatment with Either Tissue Plasminogen Activator or Streptokinase and Cyclooxygenase Inhibition

[1]  G. Perego,et al.  Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate. , 1996, European heart journal.

[2]  G. Perego,et al.  Beta-thromboglobulin plasma levels in the first week after myocardial infarction: influence of thrombolytic therapy. , 1994, American heart journal.

[3]  B. Sobel,et al.  Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. , 1993, Journal of the American College of Cardiology.

[4]  B. Lindsay,et al.  Long-term effectiveness of surgical treatment of ectopic atrial tachycardia. , 1993, Journal of the American College of Cardiology.

[5]  W. Nichols,et al.  Increased production of thromboxane A2 by coronary arteries after thrombolysis. , 1993, American heart journal.

[6]  K. Rák,et al.  Beta thromboglobulin and increased platelet activation after streptokinase treatment of acute myocardial infarction. , 1992, The American journal of cardiology.

[7]  S. Kristensen,et al.  Intravenous Acetylsalicylic Acid – Dose-Related Effects on Platelet Function and Fibrinolysis in Healthy Males , 1992, Thrombosis and Haemostasis.

[8]  C. Sylvén,et al.  Enhanced platelet function in acute myocardial infarction is attenuated by streptokinase treatment , 1992, Journal of internal medicine.

[9]  A. Rebuzzi,et al.  Importance of reperfusion on thromboxane A2 metabolite excretion after thrombolysis. , 1992, American heart journal.

[10]  P. Noris,et al.  Platelet function after in vivo and in vitro treatment with thrombolytic agents. , 1992, The American journal of cardiology.

[11]  J. Lynch,et al.  Conjunctive Enhancement of Enzymatic Thrombolysis and Prevention of Thrombotic Reocclusion With the Selective Factor Xa Inhibitor, Tick Anticoagulant Peptide: Comparison to Hirudin and Heparin in a Canine Model of Acute Coronary Artery Thrombosis , 1992, Circulation.

[12]  D. Vaughan,et al.  Streptokinase‐Induced Platelet Aggregation: Prevalence and Mechanism , 1991, Circulation.

[13]  W. Daniel,et al.  Increased Thrombin Levels During Thrombolytic Therapy in Acute Myocardial Infarction: Relevance for the Success of Therapy , 1991, Circulation.

[14]  P. Eisenberg,et al.  Role of new anticoagulants as adjunctive therapy during thrombolysis. , 1991, The American journal of cardiology.

[15]  G. FitzGerald,et al.  Antiplatelet and anticoagulant therapy during coronary thrombolysis. , 1991, Trends in cardiovascular medicine.

[16]  H. Gold,et al.  Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. , 1990, Journal of the American College of Cardiology.

[17]  H. Gold,et al.  Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. , 1990, Circulation.

[18]  G. FitzGerald,et al.  Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. , 1989, Circulation.

[19]  Janice,et al.  Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. , 1989, The Journal of clinical investigation.

[20]  G. FitzGerald,et al.  Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. , 1989, Circulation research.

[21]  E. Braunwald,et al.  Tissue plasminogen activator. , 1988, The New England journal of medicine.

[22]  J. Willerson,et al.  Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. , 1988, Circulation.

[23]  G. FitzGerald,et al.  Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. , 1988, Circulation.

[24]  A. Jaffe,et al.  Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. , 1987, Journal of the American College of Cardiology.

[25]  J. Loscalzo,et al.  Tissue plasminogen activator promotes platelet disaggregation in plasma. , 1987, The Journal of clinical investigation.

[26]  L Roy,et al.  Platelet activation in unstable coronary disease. , 1986, The New England journal of medicine.

[27]  V. Fuster,et al.  Angiographic evolution of coronary artery morphology in unstable angina. , 1986, Journal of the American College of Cardiology.

[28]  A. Schafer,et al.  Plasmin inhibition of platelet function and of arachidonic acid metabolism. , 1985, The Journal of clinical investigation.

[29]  D. Walz.  Platelet-Released Proteins as Molecular Markers for the Activation Process , 1984, Seminars in thrombosis and hemostasis.

[30]  E. Falk.  Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. , 1983, British heart journal.

[31]  K. Gallagher,et al.  Blood Flow Reductions in Stenosed Canine Coronary Arteries: Vasospasm or Platelet Aggregation? , 1982, Circulation.